Biotech China 2014
Great Debates and Updates in Breast Cancer
Hilton San Francisco Financial District
750 Kearny Street
San Francisco, California
Great Debates and Updates in Breast Cancer

Schedule of Presentations:

Friday, May 7, 2010
09:00:00 Welcome and introduction William J. Gradishar, Hope S. Rugo
09:10:00 Pre-session audience survey
09:20:00 Debate: Should all patients undergo MRI screening prior to surgery? Are all MRI scans the same? Lawrence J. Solin
09:50:00 Debate: Should trastuzumab be recommended for all women with stage I HER2+ breast cancer? William J. Gradishar, Pamela N. Munster
10:20:00 Didactic: Is gene expression profiling useful in treatment planning for node positive breast cancer? Deborah Toppmeyer
10:40:00 Questions and discussion
10:50:00 Coffee break
11:10:00 Debate: Is continuing trastuzumab in combination with chemotherapy the best treatment strategy following disease progression on trastuzumab? Virginia Kaklamani
11:40:00 Didactic: Emerging therapies for targeting HER2-positive breast cancer: current and future directions Hope S. Rugo
12:00:00 Questions and discussion
12:10:00 Lunch break
13:10:00 Debate: Should additional chemotherapy therapy be given for residual disease at the time of surgery following anthracycline and taxane based neoadjuvant chemotherapy? Mohammad Jahanzeb, Pamela N. Munster
13:40:00 Debate: Should we recommend post mastectomy radiation to all patients with node positive breast cancer? Lawrence J. Solin, Barbara L. Fowble
14:10:00 Didactic: BRCA status: impact on therapeutic decision-making Virginia Kaklamani
14:20:00 Questions and discussion
14:40:00 Coffee break
15:00:00 New Presentation New Presentation New Presentation New Presentation Denise A. Yardley, Mohammad Jahanzeb
15:30:00 Didactic: Role of new and emerging chemotherapy agents targeting the microtubule in the treatment of advanced breast cancer. Denise A. Yardley
16:00:00 Questions and discussion
16:10:00 Adjourn
17:00:00 End of day 1
Saturday, May 8, 2010
08:30:00 Introduction William J. Gradishar, Hope S. Rugo
08:35:00 Pre-session audience survey
08:45:00 Didactic: Optimal hormonal therapy and symptom management for ER-positive menopausal early stage breast cancer Deborah Toppmeyer
09:05:00 Debate: Should bevacizumab be continued beyond disease progression? Hope S. Rugo
10:55:00 Debate: Should ovarian suppression be routinely prescribed for premenopausal women with high risk early stage breast cancer? Terry Mamounas
11:25:00 Questions and discussion
11:35:00 Lunch break
12:35:00 Debate: Bisphosphonates should be routinely used to prevent disease recurrence in women with early stage breast cancer Minetta C. Liu
13:05:00 Didactic: Evolving use of circulating tumor cells and tumor markers in the management of metastatic breast cancer. Minetta C. Liu
13:35:00 Didactic: Novel genetic predictors of therapeutic resistance in breast cancer
13:55:00 Questions and discussion
14:05:00 Post-meeting audience survey
14:15:00 Adjourn
15:05:00 End of day 2
Biotech China 2014
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.